	US 12,005,106 B2
	Gut bacteria derived microvesicles for vaccine delivery
Regis Stentz, Norwich (GB); and Simon Carding, Norwich (GB)
Assigned to Quadram Institute Bioscience, Norwich (GB)
Appl. No. 17/309,067
Filed by Quadram Institute Bioscience, Norwich (GB)
PCT Filed Oct. 22, 2019, PCT No. PCT/GB2019/053007 § 371(c)(1), (2) Date Apr. 20, 2021, PCT Pub. No. WO2020/084295, PCT Pub. Date Apr. 30, 2020.
Claims priority of application No. 1817194 (GB), filed on Oct. 22, 2018.
Prior Publication US 2022/0105168 A1, Apr. 7, 2022
Int. Cl. A61K 39/02 (2006.01); A61K 39/112 (2006.01); A61P 37/04 (2006.01); C12N 15/74 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/0275 (2013.01) [A61K 39/0291 (2013.01); A61P 37/04 (2018.01); C12N 15/74 (2013.01); A61K 2039/523 (2013.01); A61K 2039/542 (2013.01); A61K 2039/543 (2013.01); A61K 2039/55594 (2013.01); A61K 2039/575 (2013.01)]

6 Claims

1. A mucosal vaccine delivered by oral and/or nasal administration for immunization against plague or Y. pestis infection in animals and humans wherein said vaccine comprises outer membrane vesicles (OMVs) including the V and/or F1 antigens of Y. pestis wherein the OMVs are produced by modified Bacteroides thetaiotaomicron (Bt) wherein the genes or mini-genes encoding the V and/or F1 Y. pestis antigens are cloned downstream of sequences encoding the N-terminal signal peptides of the Bt OMV protein OmpA.